Fresenius: “We’re not selling”

Germany-based healthcare conglomerate Fresenius tells HBI it isn't currently looking to carve off parts of its business for sale, and despite mixed H1 results it sees plenty of opportunities for growth.

HBI 2022: Balance of power in MENA is shifting

There is a risk, when looking at healthcare markets in MENA, of lumping all the countries together as one - but each market has very specific requirements, and very specific characteristics. A panel at HBI 2022 chaired by Hamid Yunis, partner at global law firm McDermott Will & Emery, investigated challenges and opportunities in the region - and how rapidly the markets are changing and why overseas players now need to work harder to impress.

Interview: Zeinab Ardeshir, CEO, PillSorted

Zeinab Ardeshir has worked in pharmacy for 17 years in multiple countries, but although she has generally enjoyed this experience, she found that a lot of her time was spent on mundane repetitive tasks which seemed like a waste for someone with her medical knowledge.

German government pushing ahead with cannabis legalisation

The German health minister is pressing ahead with plans to legalise cannabis, despite concerns from some quarters that it could be challenged at the EU level, and unresolved questions about what the regulatory framework will look like. HBI speaks to legal and policy experts, and hears that medical cannabis producers have an early adopter advantage against potential rivals - and there are health implications if legislation passes.

How can you build a successful health care science cluster in Europe?

Europe, with its often rigorous divides between research institutes and university hospitals, has fallen a long way behind power houses such as MIT/Harvard/Mass General in the generation of applied medical science. So how do you build a successful healthcare science cluster in Europe?

“For sale” Fresenius creates new $2.4bn business

As Germany-based healthcare conglomerate Fresenius looks to simplify the group's structure, selling off non-core parts of a business which currently spans hospitals, dialysis, pharma, rehabilitation and more, it is building a $2.4bn new business partnership in the US. We speak to an EU-based source familiar with Fresenius to put this all in context.

Stanley Capital acquires DSS

Stanley Capital, the London-based private equity fund, is to buy Drug Safety and Pharmacovigilance Services Solutions ("DSS") from Clario, a global clinical trials player. "DDS" specializes in pharmacovigilance - the assessment and monitoring of interactions between drugs and their effects on the human body. HBI talks to Simon Cottle, the founding partner at Stanley Capital.

Find Us